{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.6","upperLimit":"31.1","value":"25.9"},{"groupId":"OG001","lowerLimit":"9.7","upperLimit":"18.0","value":"13.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"263"},{"groupId":"OG001","value":"267"}],"units":"Participants"}],"description":"ORR is defined as the percentage of participants who achieve a best overall response of complete response (CR) + partial response (PR). ORR = CR + PR. CR is defined as disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \\< 10 millimeter (mm). Tumor-marker results must have normalized. PR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Best overall response is classified based on the overall responses assessed by study investigators according to RECIST v1.1.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ramucirumab (10 mg/kg) IV plus docetaxel (75 mg/m²) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.","id":"OG000","title":"Ramucirumab + Docetaxel"},{"description":"Placebo IV plus docetaxel (75 mg/m²) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.","id":"OG001","title":"Placebo + Docetaxel"}],"paramType":"NUMBER","populationDescription":"All randomized participants.","reportingStatus":"POSTED","timeFrame":"Randomization to Disease Progression (Up to 29.7 Months)","title":"Percentage of Participants With an Objective Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}